Protein A Resin Market Is Estimated To Witness High Growth Owing To Growing Biopharmaceutical Industry & Increasing Monoclonal Antibody Production
The Protein A Resin market is estimated to be valued at USD 1.50 Bn in 2024, exhibiting a CAGR of 9.4% over the forecast period (2024-2031). Growing biopharmaceutical industry and increasing production of monoclonal antibodies are fueling the demand for protein A resins. Furthermore, technological advancements for the development of novel resins are also expected to support the market growth.
Market Dynamics:
The biopharmaceutical industry has witnessed significant growth over the past few years owing to increasing demand for biologics and monoclonal antibodies for the treatment of various chronic diseases. Protein A resins find wide application in downstream purification process of these biotherapeutics. The expansion of biopharmaceutical industry has consequently propelled the demand for protein A resins from bioprocessing end use.
Monoclonal antibodies have emerged as the most promising therapy area with widespread clinical success across various disease indications. Growth in monoclonal antibodies indirectly increases the consumption of protein A resins as they are extensively used in capture and purification steps of mAb production process. Rising development and commercialization of novel mAbs is thus estimated to drive the protein A resin market.
Growing Demand for Therapeutic Monoclonal Antibodies is Driving the Market
One of the major drivers for the global protein A resin market is the growing demand for therapeutic monoclonal antibodies. Monoclonal antibodies have become an important component of modern medicine since their approval in the 1980s. They are now used to treat various conditions such as cancer, autoimmune disorders, and infectious diseases. Protein A resins are a critical element used in affinity chromatography during the purification and isolation of monoclonal antibodies from cell culture supernatants. With the approval of new monoclonal antibody drugs every year and wide applications in disease treatment, the demand for these therapeutic products is growing rapidly. This is directly increasing the demand for protein A resins used in downstream purification processes of monoclonal antibody production.
Increasing R&D Investments in Biopharmaceutical Industry is Fueling Market Growth
Another key driver for the protein A resin market is the rising research and development (R&D) investments in the biopharmaceutical and biotechnology sector. Biologic drugs including monoclonal antibodies offer targeted treatment options with high efficiency. However, they also require intensive research and development efforts. To capitalize on the lucrative biologics market, companies are increasingly investing in R&D activities for drug development and production process optimization. Since protein A resins are extensively used at commercial and clinical scales of monoclonal antibody production, the ramping up of R&D activities is positively impacting the demand. The growing R&D expenditures on complex biologic drugs will continue driving the need for advanced protein A resins in the coming years.
Supply Chain Issues Pose a Challenge
One of the major restraints for the protein A resin market is the supply chain issues affecting raw material procurement and product distribution. Protein A resins rely on agarose, dextran, and cellulose raw materials that are sourced from diverse geographic regions facing disruptions. The COVID-19 pandemic has severely impacted international trade and logistics, creating raw material shortages. It has also disrupted production facilities and distribution networks. As protein A resins have critical applications in biologic drug manufacturing, any glitches in the supply chain can significantly hamper end-user industries and healthcare services. Resolving raw material sourcing challenges and establishing resilient supply networks can help alleviate this restraint.
High Production Costs Limit Widespread Adoption
The high production costs associated with protein A resins present a notable challenge for market growth. While protein A affinity chromatography offers unparalleled selectivity and recovery levels, resin manufacturing involves complex engineering and a capital-intensive setup. Purification of the protein A ligand and stringent process controls add to the costs. The prices of finished protein A resins are considerably high compared to resins used in other applications. This restraints their adoption by mid-sized biopharma companies and academic/research institutes with limited budgets. Innovation in resin design and simplified production techniques can help reduce costs and expand the customer base.
Growing Biosimilars Market Spells Opportunities
The rising biosimilars market presents significant opportunities for protein A resin suppliers. Biosimilars are follow-on versions of innovator biologics that are developed after the patent expiry of original drugs. Their market acceptance is growing due to cost savings offered compared to branded biologics. Since biosimilars development and production also relies on protein A affinity chromatography, increasing competition in this field will boost resin demand. Additional capacity expansions are expected as biosimilars players enter the market.
Expanding Single-use Technologies to Drive Adoption
The expansion of single-use technologies in bioprocessing offers lucrative opportunities for the protein A resin market. To overcome facility-based constraints of traditional equipment, manufacturers are shifting to disposable single-use systems for biopharma upstream and downstream applications. This trend allows for improved flexibility, reduced automation requirements, and lower capital costs. Protein A resins are well-suited for single-use packed/fluidized bed chromatography units. Suppliers can capitalize on the opportunity by developing novel single-use resin formats optimized for plug-and-play bioprocessing.
Link: https://www.coherentmarketinsights.com/market-insight/protein-a-resin-market-231
Key Development
- In February 2024, Purolite, an Ecolab company, and Repligen Corporation, a life science company, announced the commercial launch of Praesto CH1, a novel 70 μm (micron) agarose-based affinity resin. This resin is specifically designed to purify specialized monoclonal antibodies, including bispecifics and recombinant antibody fragments.
- In January 2024, Dutch Oxitope, a developer of antibody and gene therapy products and Norwegian Arxx completed a merger to establish Calluna Pharma Inc. The newly formed company focuses on developing monoclonal antibody therapies aimed at treating inflammatory and fibrotic diseases. Calluna Pharma Inc. successfully raised USD 80.4 million (EUR 75 million) in Series A financing to advance its lead clinical program, CAL101. CAL101 is a monoclonal antibody targeting S100A4, currently in Phase 1 trials for indications related to fibrosis and inflammation.
- In March 2020, Avantor, Inc., a prominent global supplier of essential products and services to industries including life sciences, advanced technologies, and applied materials, introduced a novel recombinant Protein An affinity chromatography resin. This resin is designed specifically for purifying antibodies in the production of monoclonal antibodies (mAbs).
Key Players: GE Healthcare, Merck Millipore, Thermo Fisher Scientific, Tosoh Bioscience, Repligen, Purolite, Agarose Bead Technologies, Bio-Rad Laboratories, GenScript, PerkinElmer, Takara Bio, Expedeon, Novasep, JSR Life Sciences, Kaneka Corporation, W. R. Grace & Co., Prometic Life Sciences, and Orochem Technologies
